First-Line Afatinib starting dose of 30 mg versus 40 mg in advanced non-small cell lung cancer with uncommon EGFR mutations: A retrospective comparative study from Vietnam
Year: 2026
Type: article
Study design: Observational Study
Institution: Hanoi Medical University
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Keywords: afatinib, EGFR-mutant non-small cell lung cancer, starting dose, reduced dose, progression-free survival, objective response rate, diarrhea, adverse events, dose adjustment, Southeast Asian patients, Vietnam, first-line therapy, tyrosine kinase inhibitors, EGFR mutation, treatment toxicity, overall survival, disease control rate
Open Access status: closed
OpenAlex ID: W7236849188
